SCHEMBL233534

SCHEMBL233534

[CH2]CCCCCCCCCN

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 9/20 0.61
CA12 O43570 2/20 0.61
CA1 P00915 2/20 0.61
CA2 P00918 2/20 0.61
CA3 P07451 2/20 0.61
CA4 P22748 2/20 0.61
CA6 P23280 2/20 0.61
CA5A P35218 2/20 0.61
CA7 P43166 2/20 0.61
CA9 Q16790 2/20 0.61
CA14 Q9ULX7 2/20 0.61
CA5B Q9Y2D0 2/20 0.61
TSHR P16473 2/20 0.61
LMNA P02545 1/20 0.61
BLM P54132 1/20 0.61
NFKB1 P19838 1/20 0.54
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ALDH1A1 P00352 1/20 0.44
EPHX1 P07099 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3054555 1.00 DNM1 (0.61) DNM1CA12CA1CA2CA3
SCHEMBL1948713 1.00 DNM1 (0.61) DNM1CA12CA1CA2CA3
SCHEMBL5085490 1.00 DNM1 (0.61) DNM1CA12CA1CA2CA3
SCHEMBL2796068 1.00 DNM1 (0.61) DNM1CA12CA1CA2CA3
SCHEMBL2031871 1.00 DNM1 (0.61) DNM1CA12CA1CA2CA3
SCHEMBL4755739 1.00 DNM1 (0.61) DNM1CA12CA1CA2CA3
SCHEMBL4755756 1.00 DNM1 (0.61) DNM1CA12CA1CA2CA3
SCHEMBL4754026 1.00 DNM1 (0.61) DNM1CA12CA1CA2CA3
SCHEMBL2796425 1.00 DNM1 (0.61) DNM1CA12CA1CA2CA3
SCHEMBL233652 1.00

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3401369-B1 PROCESS FOR MAKING AN ANTI-REFLECTIVE COATING COMPOSITION AND A POROUS COATING MADE THEREFROM COVESTRO NETHERLANDS BV (NL) 2023-07-19 EP claimed
US-20230174509-A1 THERAPEUTIC USE OF PLEUROMUTILINS ARIVA MED GMBH (AT) 2023-06-08 US claimed
US-RE49481-E1 Compounds for the treatment and prophylaxis of respiratory syncytial virus disease HOFFMANN-LA ROCHE INC. (US) 2023-04-04 US claimed
EP-4135683-A1 THERAPEUTIC USE OF PLEUROMUTILINS Nabriva Therapeutics GMBH (AT) 2023-02-22 EP claimed
CN-115413238-A Therapeutic use of pleuromutilin compounds 纳布里瓦治疗有限责任公司 2022-11-29 CN claimed
CN-115368824-A Fast curing migration-free compositions based on organic polymers containing silane groups SIKA技术股份公司 2022-11-22 CN claimed
WO-2021209596-A1 THERAPEUTIC USE OF PLEUROMUTILINS Nabriva Therapeutics GmbH (AT) 2021-10-21 WO claimed
EP-3131994-B1 FAST CURING MIGRATION-FREE COMPOSITION BASED ON ORGANIC POLYMERS CONTAINING SILANE GROUPS SIKA TECH AG (CH) 2021-06-09 EP claimed
EP-3096751-B1 12-EPI-PLEUROMUTILINS Nabriva Therapeutics GmbH (AT) 2021-01-06 EP claimed
CN-105916499-B 12-epi-pleuromutilins 纳布里瓦治疗股份公司 2020-02-18 CN claimed
WO-2013020993-A1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2013-02-14 WO claimed
CN-101180275-A Tetrahydroindolone and tetrahydroindazolone derivatives SERENEX INC (US) 2008-05-14 CN claimed
US-5554339-A Process for the manufacture of wholly microfabricated biosensors I-STAT CORPORATION (US) 1996-09-10 US claimed
EP-0523965-B1 Salts of N-nitrosophenylhydroxylamine ROHM & HAAS (US) 1996-03-06 EP claimed
US-5466575-A Process for the manufacture of wholly microfabricated biosensors I-STAT CORPORATION (US) 1995-11-14 US claimed
EP-0523965-A1 Salts of N-nitrosophenylhydroxylamine ROHM AND HAAS COMPANY (US) 1993-01-20 EP claimed
US-4822872-A PREFERENTIAL ADSORPTION OF IMPURITIES ON WATER INSOLUBLE CARRIER WITH AMINE OR ALDEHYDE LIGANDS GREEN CROSS CORPORATION (JP) 1989-04-18 US claimed
US-4710491-A N-glycosylated carboxylic acid derivatives as agents for combating rheumatic diseases TROPONWERKE GMBH & CO., KG (DE) 1987-12-01 US claimed
EP-0245875-A2 Method of purifying factor VIII GREEN CROSS CORPORATION (JP) 1987-11-19 EP claimed
EP-0230242-A2 Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their use HOECHST AKTIENGESELLSCHAFT (DE) 1987-07-29 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174509-A1 THERAPEUTIC USE OF PLEUROMUTILINS MLN, PLEC, PELP1 DNM1 4766/4885CA12 450/4885CA1 3490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.